---
title: "Stryker Q4 net sales rise 11.4%, beat estimates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274204020.md"
description: "Stryker's Q4 net sales rose 11.4%, surpassing analyst expectations, with adjusted EPS increasing by 11.5%. The company forecasts 2026 organic net sales growth of 8.0% to 9.5% and adjusted EPS between $14.90 and $15.10. Key growth drivers included a 17.5% increase in MEDSURG and NEUROTECHNOLOGY sales and an 8.4% rise in the ORTHOPAEDICS segment. The average analyst rating is \"buy,\" with a median 12-month price target of $432.50, reflecting a potential 20.9% increase from its recent trading price of $357.83."
datetime: "2026-01-29T21:16:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274204020.md)
  - [en](https://longbridge.com/en/news/274204020.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274204020.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274204020.md) | [繁體中文](https://longbridge.com/zh-HK/news/274204020.md)


# Stryker Q4 net sales rise 11.4%, beat estimates

)

Overview

-   Medical technologies firm’s Q4 net sales rose 11.4%, beating analyst expectations
-   Adjusted EPS for Q4 increased 11.5%, beating analyst expectations
-   Company expects 2026 organic net sales growth of 8.0% to 9.5%

Outlook

-   Company expects 2026 organic net sales growth between 8.0% and 9.5%
-   Stryker forecasts 2026 adjusted EPS between $14.90 and $15.10
-   Company anticipates slightly positive impact from foreign exchange on 2026 results

Result Drivers

-   MEDSURG AND NEUROTECHNOLOGY GROWTH - Segment net sales increased 17.5% in Q4, driven by strong unit volume growth
-   ORTHOPAEDICS SEGMENT - Organic net sales increased 8.4% in Q4, driven by unit volume growth
-   OPERATING MARGIN IMPROVEMENT - Adjusted operating income margin increased 100 bps to 30.2% in Q4

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 net Beat $7.20 $7.12

sales bln bln (25

Analysts

)

Q4 Beat $4.47 $4.40

Adjusted (25

EPS Analysts

)

### Q4 EPS $2.20

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 24 “strong buy” or “buy”, 8 “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the medical equipment, supplies & distribution peer group is “buy”
-   Wall Street’s median 12-month price target for Stryker Corp is $432.50, about 20.9% above its January 28 closing price of $357.83
-   The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [Stryker Corporation (SYK.US)](https://longbridge.com/en/quote/SYK.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)